Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Inflammatory Bowel Diseases

  Free Subscription


Articles published in Clin Gastroenterol Hepatol

Retrieve available abstracts of 187 articles:
HTML format



Single Articles


    July 2021
  1. KHAN N, Wang L, Trivedi C, Pernes T, et al
    Efficacy of Recombinant Zoster Vaccine in Patients with Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2021 Jul 15. pii: S1542-3565(21)00754.
    PubMed     Abstract available


  2. CHAN SSM, Chen Y, Casey K, Olen O, et al
    Obesity is associated with increased risk of Crohn's disease, but not ulcerative colitis: A pooled analysis of five prospective cohort studies.
    Clin Gastroenterol Hepatol. 2021 Jul 6. pii: S1542-3565(21)00720.
    PubMed     Abstract available


  3. NARULA N, Wong ECL, Colombel JF, Riddell R, et al
    Early Change in Epithelial Neutrophilic Infiltrate Predicts Long-Term Response to Biologics in Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2021 Jul 3. pii: S1542-3565(21)00716.
    PubMed     Abstract available


    June 2021
  4. D'SILVA A, Fox DE, Nasser Y, Vallance JK, et al
    Prevalence and Risk Factors for Fatigue in Adults with Inflammatory Bowel Disease: A Systematic Review with Meta-analysis.
    Clin Gastroenterol Hepatol. 2021 Jun 30. pii: S1542-3565(21)00698.
    PubMed     Abstract available


  5. ASSCHER VER, Waars SN, van der Meulen-de Jong AE, Stuyt RJL, et al
    Deficits in geriatric assessment associate with disease activity and -burden in older patients with inflammatory bowel disease.
    Clin Gastroenterol Hepatol. 2021 Jun 18. pii: S1542-3565(21)00643.
    PubMed     Abstract available


  6. CASSINOTTI A, Corona A, Duca P, Nebuloni M, et al
    NON INVASIVE MONITORING AFTER AZATHIOPRINE WITHDRAWAL IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IN DEEP REMISSION.
    Clin Gastroenterol Hepatol. 2021 Jun 14. pii: S1542-3565(21)00642.
    PubMed     Abstract available


  7. DANESE S, Klopocka M, Scherl EJ, Romatowski J, et al
    Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study [102/120 characters including spaces].
    Clin Gastroenterol Hepatol. 2021 Jun 11. pii: S1542-3565(21)00614.
    PubMed     Abstract available


  8. AGRAWAL M, Brenner EJ, Yan Mak JW, Zhang X, et al
    COVID-19 outcomes among racial and ethnic minority individuals with inflammatory bowel disease in the United States.
    Clin Gastroenterol Hepatol. 2021 Jun 2. pii: S1542-3565(21)00599.
    PubMed    


    May 2021
  9. TROELSEN FS, Sorensen HT, Crockett SD, Pedersen L, et al
    Characteristics and survival of patients with inflammatory bowel disease and post-colonoscopy colorectal cancers.
    Clin Gastroenterol Hepatol. 2021 May 26. pii: S1542-3565(21)00577.
    PubMed     Abstract available


  10. BERINSTEIN JA, Sheehan J, Dias M, Berinstein EM, et al
    Tofacitinib for Biologic-Experienced Hospitalized Patients with Acute Severe Ulcerative Colitis: A Retrospective Case-Control Study.
    Clin Gastroenterol Hepatol. 2021 May 25. pii: S1542-3565(21)00576.
    PubMed     Abstract available


  11. KAYAL M, Ungaro RC, Riggs A, Kamal K, et al
    Ileal Pouch Anal Anastomosis for the Management of Ulcerative Colitis is Associated with Significant Disability.
    Clin Gastroenterol Hepatol. 2021 May 22. pii: S1542-3565(21)00571.
    PubMed     Abstract available


  12. AHMED W, Scott FI
    Closing the gap: the real-world risk of serious infections with vedolizumab in comparison to anti-TNF therapy in inflammatory bowel disease.
    Clin Gastroenterol Hepatol. 2021 May 19. pii: S1542-3565(21)00564.
    PubMed    


  13. CONSTANT BD, Dutmer CM, Arnold MA, Hall C, et al
    Cytotoxic T-Lymphocyte-Associated Antigen 4 Haploinsufficiency Mimics Difficult to Treat Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2021 May 6. pii: S1542-3565(21)00504.
    PubMed    


    April 2021
  14. CON D, Vasudevan A, van Langenberg DR
    Predictive Scores in Acute Severe Ulcerative Colitis: Which, What and When are the Decision Points We Should Target?
    Clin Gastroenterol Hepatol. 2021 Apr 24. pii: S1542-3565(21)00469.
    PubMed    


  15. VOLGER S, Scherl E
    Biologics for Inflammatory Bowel Disease and their Safety in Pregnancy.
    Clin Gastroenterol Hepatol. 2021 Apr 14. pii: S1542-3565(21)00449.
    PubMed    


  16. ROTH K, Berinstein JA
    Reply: A Patient Perspective on Contemporary Risk of Surgery in Patients with Ulcerative Colitis and Crohn's Disease.
    Clin Gastroenterol Hepatol. 2021 Apr 8. pii: S1542-3565(21)00446.
    PubMed    


  17. BHATTACHARYA S, Marciano BE, Malech HL, Quezado M, et al
    Safety and efficacy of ustekinumab in the inflammatory bowel disease of chronic granulomatous disease.
    Clin Gastroenterol Hepatol. 2021 Apr 1. pii: S1542-3565(21)00349.
    PubMed    


  18. SORRENTINO D, Geraci M, Kuballa A
    Diagnosis of Preclinical Crohn's Disease: Hurdles, Challenges, and Hopes.
    Clin Gastroenterol Hepatol. 2021;19:857-858.
    PubMed    


    March 2021
  19. AHMED W, Galati J, Kumar A, Christos PJ, et al
    Dual Biologic or Small Molecule Therapy for Treatment of Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
    Clin Gastroenterol Hepatol. 2021 Mar 30. pii: S1542-3565(21)00344.
    PubMed     Abstract available


  20. LOPES EW, Lebwohl B, Burke KE, Ivey KL, et al
    DIETARY GLUTEN INTAKE IS NOT ASSOCIATED WITH RISK OF INFLAMMATORY BOWEL DISEASE IN U.S. ADULTS WITHOUT CELIAC DISEASE.
    Clin Gastroenterol Hepatol. 2021 Mar 25. pii: S1542-3565(21)00339.
    PubMed     Abstract available


  21. DALAL RS, Esckilsen S, Barnes EL, Pruce JC, et al
    Predictors and outcomes of ustekinumab dose intensification in ulcerative colitis: a multicenter cohort study.
    Clin Gastroenterol Hepatol. 2021 Mar 25. pii: S1542-3565(21)00338.
    PubMed    


  22. NAMBU R, Warner N, Mulder DJ, Kotlarz D, et al
    A Systematic Review of Monogenic Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2021 Mar 18. pii: S1542-3565(21)00331.
    PubMed     Abstract available


  23. OKAMOTO T, Fukuda K
    Long-term outcomes in asymptomatic ulcerative colitis diagnosed during screening colonoscopy.
    Clin Gastroenterol Hepatol. 2021 Mar 11. pii: S1542-3565(21)00275.
    PubMed    


  24. SANDBORN WJ, Peyrin-Biroulet L, Sharara AI, Su C, et al
    Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status.
    Clin Gastroenterol Hepatol. 2021 Mar 5. pii: S1542-3565(21)00222.
    PubMed     Abstract available


  25. ALAMEEL T, Al Sulais E
    Risk of HBV Reactivation Among IBD patients With Occult Hepatitis B Virus Infection.
    Clin Gastroenterol Hepatol. 2021;19:621-622.
    PubMed    


  26. ANANTHAKRISHNAN AN, Deshpande V
    It Is All in the Fine Print: A Call for a Histopathology Checklist for IBD.
    Clin Gastroenterol Hepatol. 2021;19:446-447.
    PubMed    


    February 2021
  27. AKHTAR HJ, Nguyen TM, Ma C, Jairath V, et al
    Vedolizumab for the treatment of Non-Inflammatory Bowel Disease Related Enteropathy.
    Clin Gastroenterol Hepatol. 2021 Feb 19. pii: S1542-3565(21)00204.
    PubMed    


  28. JANGI S, Holmer AK, Dulai PS, Boland B, et al
    Spatial Evolution of Histologic and Endoscopic Healing in Left and Right Colon in Patients with Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2021 Feb 5. pii: S1542-3565(21)00108.
    PubMed     Abstract available


  29. AKIYAMA S, Ollech JE, Rai V, Glick LR, et al
    Endoscopic phenotype of the J pouch in patients with inflammatory bowel disease: A new classification for pouch outcomes.
    Clin Gastroenterol Hepatol. 2021 Feb 4. pii: S1542-3565(21)00111.
    PubMed     Abstract available


  30. LONG MD, Siegel CA, Abraham BP, Chiorean M, et al
    Day Care Attendance and Infectious Complications in Children Born to Mothers with Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2021 Feb 4. pii: S1542-3565(21)00104.
    PubMed    


    January 2021
  31. LAURAIN PA, Guillo L, D'Amico F, Netter P, et al
    Incidence of and risk factors for colorectal strictures in ulcerative colitis: a multicenter study.
    Clin Gastroenterol Hepatol. 2021 Jan 22. pii: S1542-3565(21)00078.
    PubMed     Abstract available


  32. VAN DER SLOOT KWJ, Tiems JL, Visschedijk MC, Festen EAM, et al
    Cigarette smoke increases risk for colorectal neoplasia in inflammatory bowel disease.
    Clin Gastroenterol Hepatol. 2021 Jan 13. pii: S1542-3565(21)00018.
    PubMed     Abstract available


  33. DAI C, Huang YH, Jiang M
    Two Types of Fecal Tests in Patients With Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2021;19:209.
    PubMed    


  34. DEL HOYO J, Aguas M
    Cost-effectiveness of Telemedicine-directed Specialized vs Standard Care for Patients With Inflammatory Bowel Diseases in a Randomized Trial.
    Clin Gastroenterol Hepatol. 2021;19:206-207.
    PubMed    


  35. BRENNER EJ, Kappelman MD
    Working Together to Meet the Needs of Patients With Inflammatory Bowel Diseases.
    Clin Gastroenterol Hepatol. 2021;19:210-211.
    PubMed    


  36. NAGANUMA M, Kanai T
    Reply.
    Clin Gastroenterol Hepatol. 2021;19:209-210.
    PubMed    


    December 2020
  37. KIRCHGESNER J, Desai RJ, Beaugerie L, Schneeweiss S, et al
    Risk of serious infections with vedolizumab versus tumor necrosis factor antagonists in patients with inflammatory bowel disease.
    Clin Gastroenterol Hepatol. 2020 Dec 30. pii: S1542-3565(20)31726.
    PubMed     Abstract available


  38. GUILLO L, Uzzan M, Beaugerie L, Gornet JM, et al
    Impact of HIV infection on the course of inflammatory bowel disease and drug safety profile: a multicenter GETAID study.
    Clin Gastroenterol Hepatol. 2020 Dec 24. pii: S1542-3565(20)31719.
    PubMed     Abstract available


  39. KHANNA R, Ma C, Jairath V, Casteele NV, et al
    Endoscopic Assessment of Inflammatory Bowel Disease Activity in Clinical Trials.
    Clin Gastroenterol Hepatol. 2020 Dec 15. pii: S1542-3565(20)31674.
    PubMed     Abstract available


  40. MA C, Jeyarajah J, Guizzetti L, Parker CE, et al
    Modeling Endoscopic Improvement after Induction Treatment with Mesalamine in Patients with Mild-to-Moderate Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2020 Dec 3. pii: S1542-3565(20)31630.
    PubMed     Abstract available


    November 2020
  41. WANG CY, Chen WL, Cheng-Chung Wei J
    Link Between Inflammatory Bowel Disease and Risk of Chronic Kidney Disease.
    Clin Gastroenterol Hepatol. 2020 Nov 21. pii: S1542-3565(20)31498.
    PubMed    


  42. VAJRAVELU RK, Copelovitch L, Denburg MR
    Letter title: "Link between inflammatory bowel disease and risk of chronic kidney disease" by Wang and colleagues.
    Clin Gastroenterol Hepatol. 2020 Nov 20. pii: S1542-3565(20)31565.
    PubMed    


  43. BRAAT H, Parikh K, Peppelenbosch MP
    Complete Resolution of Mucosal Neutrophils May Predict Non-fatigue in Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2020 Nov 19. pii: S1542-3565(20)31559.
    PubMed    


  44. GRACIE DJ, Ford AC
    Bugs and the Brain in Inflammatory Bowel Disease: A Novel Treatment Target?
    Clin Gastroenterol Hepatol. 2020 Nov 6. pii: S1542-3565(20)31434.
    PubMed    


  45. D'AMICO F, Danese S, Peyrin-Biroulet L
    Systematic Review on Inflammatory Bowel Disease Patients With Coronavirus Disease 2019: It Is Time to Take Stock.
    Clin Gastroenterol Hepatol. 2020;18:2689-2700.
    PubMed     Abstract available


    October 2020
  46. SANDBORN WJ, Peyrin-Biroulet L, Quirk D, Wang W, et al
    Efficacy and Safety of Extended Induction with Tofacitinib for the Treatment of Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2020 Oct 27. pii: S1542-3565(20)31496.
    PubMed     Abstract available


  47. TSAI L, Ma C, Dulai PS, Prokop LJ, et al
    Contemporary Risk of Surgery in Patients with Ulcerative Colitis and Crohn's Disease: A Meta-Analysis of Population-based Cohorts.
    Clin Gastroenterol Hepatol. 2020 Oct 27. pii: S1542-3565(20)31497.
    PubMed     Abstract available


  48. OLLECH JE, Avni-Biron I, Glick L, Haider H, et al
    Effective Treatment of Acute Severe Ulcerative Colitis in Pregnancy Is Associated with Good Maternal and Fetal Outcomes.
    Clin Gastroenterol Hepatol. 2020 Oct 22. pii: S1542-3565(20)31493.
    PubMed     Abstract available


  49. LI YM, Stettler I, Oungpasuk K
    Association Between Provider Connectedness and Inflammatory Bowel Disease Outcomes.
    Clin Gastroenterol Hepatol. 2020 Oct 22. pii: S1542-3565(20)31291.
    PubMed    


  50. STEENHOLDT C, Jensen JT, Brynskov J, Moller AM, et al
    Patient Satisfaction of Propofol Versus Midazolam and Fentanyl Sedation During Colonoscopy in Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2020 Oct 22. pii: S1542-3565(20)31495.
    PubMed     Abstract available


  51. VEDAMURTHY A, Gangasani N, Ananthakrishnan AN
    Vedolizumab or TNF-antagonist use and risk of new or recurrent cancer in patients with inflammatory bowel disease with prior malignancy: A retrospective cohort study.
    Clin Gastroenterol Hepatol. 2020 Oct 13. pii: S1542-3565(20)31396.
    PubMed     Abstract available


  52. KHOUDARI G, Mansoor E, Click B, Alkhayyat M, et al
    Rates of Intestinal Resection and Colectomy in Inflammatory Bowel Disease Patients after Initiation of Biologics: A Cohort Study.
    Clin Gastroenterol Hepatol. 2020 Oct 13. pii: S1542-3565(20)31397.
    PubMed     Abstract available


  53. NAESSENS D, Cameron C, Hoaglin DC
    Network Meta-Analysis of Ulcerative Colitis Pharmacotherapies: Carryover Effects from Induction and Bias of the Results.
    Clin Gastroenterol Hepatol. 2020 Oct 13. pii: S1542-3565(20)31428.
    PubMed    


  54. BRENNER EJ, Pigneur B, Focht G, Zhang X, et al
    BENIGN EVOLUTION OF SARS-CoV2 INFECTIONS IN CHILDREN WITH INFLAMMATORY BOWEL DISEASE: RESULTS FROM TWO INTERNATIONAL DATABASES.
    Clin Gastroenterol Hepatol. 2020 Oct 12. pii: S1542-3565(20)31399.
    PubMed    


  55. COLOMBEL JF, Osterman MT, Thorpe AJ, Salese L, et al
    Maintenance of Remission With Tofacitinib Therapy in Patients With Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2020 Oct 8. pii: S1542-3565(20)31389.
    PubMed     Abstract available


  56. LUKIN D, Faleck D, Xu R, Zhang Y, et al
    Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2020 Oct 8. pii: S1542-3565(20)31388.
    PubMed     Abstract available


    September 2020
  57. KIM HJ, Shah SC, Hann HJ, Kazmi SZ, et al
    Familial Risk of Inflammatory Bowel Disease - A Population-based Cohort study in South Korea.
    Clin Gastroenterol Hepatol. 2020 Sep 30. pii: S1542-3565(20)31384.
    PubMed     Abstract available


  58. DIMKE H, Winther-Jensen M, Allin KH, Lund L, et al
    Risk of Urolithiasis in Patients with Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2020 Sep 29. pii: S1542-3565(20)31379.
    PubMed     Abstract available


  59. SANDBORN WJ, Ferrante M, Bhandari BR, Berliba E, et al
    Efficacy and Safety of Continued Treatment with Mirikizumab in a Phase 2 Trial of Patients with Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2020 Sep 17. pii: S1542-3565(20)31289.
    PubMed     Abstract available


  60. NIELSEN OH, Gubatan JM, Juhl CB, Streett SE, et al
    Biologics for Inflammatory Bowel Disease and their Safety in Pregnancy: A Systematic Review and Meta-analysis.
    Clin Gastroenterol Hepatol. 2020 Sep 12. pii: S1542-3565(20)31281.
    PubMed     Abstract available


  61. MAGRO F, Alves C, Lopes J, Lopes S, et al
    Histologic Features of Colon Biopsies (Geboes Score) Associated With Progression of Ulcerative Colitis for the First 36 Months After Biopsy.
    Clin Gastroenterol Hepatol. 2020 Sep 10. pii: S1542-3565(20)31274.
    PubMed     Abstract available


  62. FAIRBRASS KM, Gracie DJ
    Mood and Treatment Persistence in Inflammatory Bowel Disease: Time to Consider Integrated Models of Care?
    Clin Gastroenterol Hepatol. 2020 Sep 1. pii: S1542-3565(20)31227.
    PubMed    


    August 2020
  63. STORAN D, Doherty GA, Cullen G
    Ustekinumab 90 mg Every 2 Weeks for the Treatment of Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2020 Aug 30. pii: S1542-3565(20)31079.
    PubMed    


  64. NICCUM B, Moninuola O, Miller K, Khalili H, et al
    Opioid use among patients with inflammatory bowel disease: A systematic review and meta-analysis.
    Clin Gastroenterol Hepatol. 2020 Aug 21. pii: S1542-3565(20)31150.
    PubMed     Abstract available


  65. PAPA A, Lopetuso LR, Tursi A
    Inflammatory Bowel Disease Patients With Coronavirus Disease 2019: The Picture Is Taking Shape.
    Clin Gastroenterol Hepatol. 2020 Aug 18. pii: S1542-3565(20)31142.
    PubMed    


  66. GILMORE R, Hilley P, Srinivasan A, Choy MC, et al
    Tofacitinib is Safe and Effective When Used in Combination With Infliximab for the Management of Refractory Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2020 Aug 16. pii: S1542-3565(20)31008.
    PubMed    


  67. LO B, Zhao M, Vind I, Burisch J, et al
    The risk of extra-intestinal cancer in inflammatory bowel disease: a systematic review and meta-analysis of population-based cohort studies.
    Clin Gastroenterol Hepatol. 2020 Aug 12. pii: S1542-3565(20)31124.
    PubMed     Abstract available


  68. STEVENS TW, Gecse K, Turner JR, de Hertogh G, et al
    Diagnostic Accuracy of Fecal Calprotectin Concentration in Evaluating Therapeutic Outcomes of Patients With Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2020 Aug 12. pii: S1542-3565(20)31128.
    PubMed     Abstract available


  69. BERINSTEIN JA, Steiner CA, Higgins PDR
    Reply to Tofacitinib is safe and effective when used in combination with Infliximab for the management of Refractory Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2020 Aug 12. pii: S1542-3565(20)31132.
    PubMed    


  70. LAHARIE D, Bourreille A, Branche J, Allez M, et al
    Evolution of endoscopic lesions in steroid-refractory acute severe ulcerative colitis responding to infliximab or cyclosporine.
    Clin Gastroenterol Hepatol. 2020 Aug 7. pii: S1542-3565(20)31078.
    PubMed     Abstract available


    July 2020
  71. AREBI N, Dyall L, Kamperidis N
    A User's Guide to De-Escalating Immunomodulator and Biologic Therapy in Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2020 Jul 27. pii: S1542-3565(20)30920.
    PubMed    


  72. CHHIBBA T, Guizzetti L, Seow CH, Lu C, et al
    Frequency of Opioid Prescription at Emergency Department Discharge in Patients with Inflammatory Bowel Disease: A Nationwide Analysis (2006-2017).
    Clin Gastroenterol Hepatol. 2020 Jul 16. pii: S1542-3565(20)30982.
    PubMed     Abstract available


  73. DOLOVICH C, Bernstein CN, Singh H, Nugent Z, et al
    Anxiety and Depression Leads to Anti-Tumor Necrosis Factor Discontinuation in Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2020 Jul 12. pii: S1542-3565(20)30974.
    PubMed     Abstract available


  74. DEEPAK P, Alayo QA, Khatiwada A, Lin B, et al
    Safety of Tofacitinib in a Real-World Cohort of Patients With Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2020 Jul 3. pii: S1542-3565(20)30913.
    PubMed     Abstract available


    June 2020
  75. HWANG C, Issokson K, Giguere-Rich C, Reddy S, et al
    Development and Pilot Testing of the Inflammatory Bowel Disease Nutrition Care Pathway.
    Clin Gastroenterol Hepatol. 2020 Jun 26. pii: S1542-3565(20)30902.
    PubMed    


  76. SCAIOLI E, Salice M, Belluzzi A
    Omega-3 as a Part of the Dietary Guidance for Patients with Ulcerative Colitis: Beyond the Natural Sources.
    Clin Gastroenterol Hepatol. 2020 Jun 25. pii: S1542-3565(20)30760.
    PubMed    


  77. BARNES EL, Herfarth HH, Kappelman MD, Zhang X, et al
    Incidence, Risk Factors, and Outcomes of Pouchitis and Pouch-related Complications in Patients with Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2020 Jun 22. pii: S1542-3565(20)30846.
    PubMed     Abstract available


  78. CARON B, Arondel Y, Reimund JM
    Covid-19 and inflammatory bowel disease: questions on incidence, severity, and impact of treatment?
    Clin Gastroenterol Hepatol. 2020 Jun 6. pii: S1542-3565(20)30764.
    PubMed    


  79. PAPAMICHAEL K, Cheifetz AS
    Therapeutic Drug Monitoring and Safety of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2020 Jun 5. pii: S1542-3565(20)30638.
    PubMed    


    May 2020
  80. FRITSCH J, Garces L, Quintero MA, Pignac-Kobinger J, et al
    Low-fat, High-fiber Diet Reduces Markers of Inflammation and Dysbiosis and Improves Quality of Life in Patients With Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2020 May 20. pii: S1542-3565(20)30685.
    PubMed     Abstract available


  81. MELNYK J, Stefanov DG, Sultan K
    Inflammatory Bowel Disease and Corticosteroid induced Diabetes Mellitus.
    Clin Gastroenterol Hepatol. 2020 May 17. pii: S1542-3565(20)30678.
    PubMed    


  82. DULAI PS, Sandborn WJ, Murphy J
    Microsimulation Model to Determine the Cost Effectiveness of Treat to Target Strategies for Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2020 May 10. pii: S1542-3565(20)30644.
    PubMed     Abstract available


  83. CHENG D, Cushing KC, Cai T, Ananthakrishnan AN, et al
    Safety and Efficacy of Tumor Necrosis Factor Antagonists in Older Patients With Ulcerative Colitis: Patient-Level Pooled Analysis of Data From Randomized Trials.
    Clin Gastroenterol Hepatol. 2020 May 1. pii: S1542-3565(20)30615.
    PubMed     Abstract available


  84. FOTEINOGIANNOPOULOU K, Orfanoudaki E, Koutroubakis IE
    Keeping on the high quality of healthcare in Greek Inflammatory Bowel Disease patients in the SARS-CoV-2 era.
    Clin Gastroenterol Hepatol. 2020 May 1. pii: S1542-3565(20)30621.
    PubMed    


    April 2020
  85. ALLOCCA M, Fiorino G, Zallot C, Furfaro F, et al
    Incidence and patterns of COVID-19 among inflammatory bowel disease patients from the Nancy and Milan cohorts.
    Clin Gastroenterol Hepatol. 2020 Apr 30. pii: S1542-3565(20)30616.
    PubMed    


  86. EL-MATARY W, Guthery SL, Amir AZ, DiGuglielmo M, et al
    Colorectal Dysplasia and Cancer in Pediatric-onset Ulcerative Colitis Associated with Primary Sclerosing Cholangitis.
    Clin Gastroenterol Hepatol. 2020 Apr 29. pii: S1542-3565(20)30600.
    PubMed    


  87. BATTAT R, Hemperly A, Truong S, Whitmire N, et al
    Baseline Clearance of Infliximab is Associated with Requirement for Colectomy in Patients with Acute Severe Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2020 Apr 26. pii: S1542-3565(20)30530.
    PubMed     Abstract available


  88. HANZEL J, Ma C, Marshall JK, Feagan BG, et al
    Managing Inflammatory Bowel Disease During COVID-19: Summary of Recommendations from Gastrointestinal Societies.
    Clin Gastroenterol Hepatol. 2020 Apr 21. pii: S1542-3565(20)30529.
    PubMed    


  89. ALLOCCA M, Fiorino G, Furfaro F, Gilardi D, et al
    Maintaining the quality standards of care for inflammatory bowel disease patients during the COVID-19 pandemic.
    Clin Gastroenterol Hepatol. 2020 Apr 15. pii: S1542-3565(20)30524.
    PubMed    


  90. LAI SW, Kuo YH, Liao KF
    Association Between Inflammatory Bowel Disease and Diabetes Mellitus.
    Clin Gastroenterol Hepatol. 2020;18:1002-1003.
    PubMed    


  91. ONA S, Long M, Mitchell C
    Reply.
    Clin Gastroenterol Hepatol. 2020;18:1002.
    PubMed    


    March 2020
  92. MUIR AJ
    What Clues Can We Use From Primary Sclerosing Cholangitis With Inflammatory Bowel Disease Phenotypes?
    Clin Gastroenterol Hepatol. 2020 Mar 30. pii: S1542-3565(20)30430.
    PubMed    


  93. PAPAMICHAEL K, Clarke WT, Casteele NV, Germansky KA, et al
    Comparison between assays used for therapeutic drug monitoring of infliximab and adalimumab in inflammatory bowel disease.
    Clin Gastroenterol Hepatol. 2020 Mar 5. pii: S1542-3565(20)30273.
    PubMed    


    February 2020
  94. NITTALA R, Singh A
    Effects of Apremilast, an Oral Inhibitor of Phosphodiesterase 4, in a Randomized Trial of Patients with Active Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2020 Feb 25. pii: S1542-3565(20)30208.
    PubMed    


  95. SONNENBERG A, Turner KO, Genta RM
    Comorbid Occurrence of Eosinophilic Esophagitis and Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2020 Feb 14. pii: S1542-3565(20)30183.
    PubMed    


  96. LEVINE A, Rhodes JM, Lindsay JO, Abreu MT, et al
    Dietary Guidance for Patients with Inflammatory Bowel Disease from the International Organization for the Study of Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2020 Feb 14. pii: S1542-3565(20)30185.
    PubMed     Abstract available


  97. KWAPISZ L, Raffals LE, Bruining DH, Pardi DS, et al
    Combination Biologic Therapy in Inflammatory Bowel Disease: Experience from a Tertiary Care Center.
    Clin Gastroenterol Hepatol. 2020 Feb 14. pii: S1542-3565(20)30186.
    PubMed    


  98. DULAI PS, Singh S, Casteele NV, Meserve J, et al
    Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2020 Feb 13. pii: S1542-3565(20)30174.
    PubMed     Abstract available


  99. PANSART C, Roblin X, Paul S
    Preanalytical Heterogeneity in Fecal Calprotectin Measurement Needs To Be Considered for Tight Control.
    Clin Gastroenterol Hepatol. 2020;18:524-525.
    PubMed    


  100. KENNEDY NA, Lees CW
    Reply.
    Clin Gastroenterol Hepatol. 2020;18:526.
    PubMed    


  101. COZIJNSEN MA, Turner D
    Reply.
    Clin Gastroenterol Hepatol. 2020;18:525-526.
    PubMed    


    January 2020
  102. MAGRO F, Estevinho MM
    Do Neutrophils Contribute to Development of Crohn's Disease and Ulcerative Colitis?"
    Clin Gastroenterol Hepatol. 2020 Jan 30. pii: S1542-3565(20)30111.
    PubMed    


  103. LORES T, Goess C, Mikocka-Walus A, Collins KL, et al
    Integrated Psychological Care Reduces Healthcare Costs at a Hospital-Based Inflammatory Bowel Disease Service.
    Clin Gastroenterol Hepatol. 2020 Jan 30. pii: S1542-3565(20)30109.
    PubMed     Abstract available


  104. MA C, Smith M, Guizzetti L, Panaccione R, et al
    Assessing National Trends and Disparities in Ambulatory, Emergency Department, and Inpatient Visits for Inflammatory Bowel Disease in the United States (2005-2016).
    Clin Gastroenterol Hepatol. 2020 Jan 24. pii: S1542-3565(20)30102.
    PubMed     Abstract available


  105. DANESE S, Fiorino G, Peyrin-Biroulet L
    Positioning therapies in ulcerative colitis.
    Clin Gastroenterol Hepatol. 2020 Jan 23. pii: S1542-3565(20)30096.
    PubMed     Abstract available


  106. SINGH S, Murad MH, Fumery M, Dulai PS, et al
    First- and Second-line Pharmacotherapies for Patients with Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis.
    Clin Gastroenterol Hepatol. 2020 Jan 13. pii: S1542-3565(20)30044.
    PubMed     Abstract available


  107. LE BAUT G, Kirchgesner J, Amiot A, Lefevre JH, et al
    A Scoring System to Determine Patients' Risk of Colectomy Within 1 y After Hospital Admission for Acute Severe Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2020 Jan 9. pii: S1542-3565(20)30029.
    PubMed     Abstract available


  108. KAUR M, Dalal RL, Shaffer S, Schwartz DA, et al
    Inpatient Management of Inflammatory Bowel Disease Related Complications.
    Clin Gastroenterol Hepatol. 2020 Jan 9. pii: S1542-3565(20)30034.
    PubMed     Abstract available


  109. DANESE S, Neurath MF, Kopon A, Zakko SF, et al
    Effects of Apremilast, an Oral Inhibitor of Phosphodiesterase 4, in a Randomized Trial of Patients With Active Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2020 Jan 8. pii: S1542-3565(20)30005.
    PubMed     Abstract available


  110. RODA G, Lleo A, Danese S, Aghemo A, et al
    All That Glitters is Not Gold in Vedolizumab Therapy for Patients With Inflammatory Bowel Diseases and Primary Sclerosing Cholangitis.
    Clin Gastroenterol Hepatol. 2020;18:51-53.
    PubMed    


  111. DREESEN E, Gils A
    Reply.
    Clin Gastroenterol Hepatol. 2020;18:262-263.
    PubMed    


  112. DAI C, Jiang M, Sun MJ
    Monitoring a Combination of Calprotectin and Infliximab Identifies Patients With Mucosal Healing of Crohn's Disease.
    Clin Gastroenterol Hepatol. 2020;18:262.
    PubMed    


    December 2019
  113. HIRTEN RP, Lakatos PL, Halfvarson J, Colombel JF, et al
    A Users Guide to De-escalating Immunomodulator and Biologic Therapy in Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2019 Dec 27. pii: S1542-3565(19)31499.
    PubMed     Abstract available


  114. SIEGEL CA, Thompson KD, Walls D, Gollins J, et al
    Crohn's disease patients' and gastroenterologists' perspectives towards de-escalating inflammatory bowel disease therapy.
    Clin Gastroenterol Hepatol. 2019 Dec 27. pii: S1542-3565(19)31498.
    PubMed    


  115. PAI RK, Hartman DJ, Rivers CR, Regueiro M, et al
    Complete Resolution of Mucosal Neutrophils Associates With Improved Long-Term Clinical Outcomes of Patients With Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2019 Dec 13. pii: S1542-3565(19)31438.
    PubMed     Abstract available


  116. ADEDOKUN OJ, Xu Z, Marano C, O'Brien C, et al
    Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative Colitis: Ustekinumab PK and exposure-response in UC.
    Clin Gastroenterol Hepatol. 2019 Dec 6. pii: S1542-3565(19)31403.
    PubMed     Abstract available


  117. LAI SW
    Herpes Zoster Vaccine in Older Adults With Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2019;17:2823.
    PubMed    


    November 2019
  118. BERGQUIST A, Stokkeland K, Bottai M, Soderberg-Lofdal K, et al
    Reply - Associations between drug exposure and outcomes in patients with primary sclerosing cholangitis and inflammatory bowel disease.
    Clin Gastroenterol Hepatol. 2019 Nov 12. pii: S1542-3565(19)31276.
    PubMed    


    October 2019
  119. VILLUMSEN M, Jess T, Allin KH
    Association between inflammatory bowel disease and diabetes mellitus - study population matters.
    Clin Gastroenterol Hepatol. 2019 Oct 10. pii: S1542-3565(19)31104.
    PubMed    


  120. FUNG BM, Ali AH, Tabibian JH
    Associations between drug exposure and outcomes in patients with primary sclerosing cholangitis and inflammatory bowel disease.
    Clin Gastroenterol Hepatol. 2019 Oct 5. pii: S1542-3565(19)31095.
    PubMed    


  121. BARNES EL, Lightner AL, Regueiro M
    Peri-operative and Post-operative Management of Patients with Crohn's Disease and Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2019 Oct 4. pii: S1542-3565(19)31091.
    PubMed     Abstract available


    September 2019
  122. MA C, Sandborn WJ, D'Haens GR, Zou G, et al
    Discordance Between Patient-Reported Outcomes and Mucosal Inflammation in Patients With Mild to Moderate Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2019 Sep 20. pii: S1542-3565(19)31027.
    PubMed     Abstract available


  123. CASAVANT E, Park KT, Elias JE
    Proteomic discovery of stool protein biomarkers for distinguishing pediatric inflammatory bowel disease flares.
    Clin Gastroenterol Hepatol. 2019 Sep 6. pii: S1542-3565(19)30974.
    PubMed    


    August 2019
  124. ANANTHAKRISHNAN AN, Cagan A, Cai T, Gainer VS, et al
    Use of narrative concepts in the EHR to validate genetic determinants of treatment response in a virtual inflammatory bowel disease cohort.
    Clin Gastroenterol Hepatol. 2019 Aug 9. pii: S1542-3565(19)30861.
    PubMed    


  125. O'CONNOR A, Gracie DJ, Hamlin PJ, Ford AC, et al
    Letter: Predictors of Dyspareunia Among Female Patients with Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2019 Aug 8. pii: S1542-3565(19)30854.
    PubMed    


  126. NAGANUMA M, Kobayashi T, Nasuno M, Motoya S, et al
    Significance of Conducting 2 Types of Fecal Tests in Patients with Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2019 Aug 5. pii: S1542-3565(19)30843.
    PubMed     Abstract available


  127. JESS T, Jensen BW, Andersson M, Villumsen M, et al
    Inflammatory Bowel Disease Increases Risk of Type 2 Diabetes in a Nationwide Cohort Study.
    Clin Gastroenterol Hepatol. 2019 Aug 5. pii: S1542-3565(19)30841.
    PubMed     Abstract available


  128. REINISCH W, Gottlieb K, Colombel JF, Danese S, et al
    Comparison of the EMA and FDA Guidelines on Ulcerative Colitis Drug Development.
    Clin Gastroenterol Hepatol. 2019;17:1673-1679.
    PubMed     Abstract available


    July 2019
  129. LICHTENSTEIN GR, Shahabi A, Seabury SA, Lakdawalla DN, et al
    Lifetime Economic Burden of Crohn's Disease and Ulcerative Colitis by Age at Diagnosis.
    Clin Gastroenterol Hepatol. 2019 Jul 18. pii: S1542-3565(19)30765.
    PubMed     Abstract available


  130. LE BERRE C, Ananthakrishnan AN, Danese S, Singh S, et al
    Ulcerative Colitis and Crohn's Disease Have the Same Burden and Goals for Treatment.
    Clin Gastroenterol Hepatol. 2019 Jul 10. pii: S1542-3565(19)30738.
    PubMed     Abstract available


  131. KISIEL JB, Mahoney DW, Taylor WR, Klepp P, et al
    Response to: Value of VAV3 methylation in stool DNA might be restricted to non-thiopurine treated inflammatory bowel disease patients (CGH-D-19-01071).
    Clin Gastroenterol Hepatol. 2019 Jul 4. pii: S1542-3565(19)30729.
    PubMed    


    June 2019
  132. ISRAEL A, Christensen B, El Jurdi K, Rai V, et al
    Follow-Up of Ulcerative Colitis Patients Who Have Achieved Histological Normalization.
    Clin Gastroenterol Hepatol. 2019 Jun 19. pii: S1542-3565(19)30663.
    PubMed    


  133. LAM SY, Yu J, Peppelenbosch MP
    Value of VAV3 methylation in stool DNA might be restricted to non-thiopurine treated inflammatory bowel disease patients.
    Clin Gastroenterol Hepatol. 2019 Jun 17. pii: S1542-3565(19)30658.
    PubMed    


  134. KHALILI H
    Reply.
    Clin Gastroenterol Hepatol. 2019;17:1418-1419.
    PubMed    


  135. YANG XY, Chen PF, He JH
    High Consumption of Sweetened Beverages Might Increase the Risk of Inflammatory Bowel Diseases.
    Clin Gastroenterol Hepatol. 2019;17:1417-1418.
    PubMed    


    May 2019
  136. SINGH S, Proudfoot JA, Dulai PS, Xu R, et al
    Efficacy and Speed of Induction of Remission of Infliximab vs Golimumab for Patients With Ulcerative Colitis, Based on Data From Clinical Trials.
    Clin Gastroenterol Hepatol. 2019 May 17. pii: S1542-3565(19)30529.
    PubMed     Abstract available


  137. KIRCHGESNER J, Svrcek M, Le Gall G, Landman C, et al
    Nancy Index Scores of Chronic Inflammatory Bowel Disease Activity Associate With Development of Colorectal Neoplasia.
    Clin Gastroenterol Hepatol. 2019 May 11. pii: S1542-3565(19)30511.
    PubMed     Abstract available


  138. SANDS BE, Taub PR, Armuzzi A, Friedman GS, et al
    Tofacitinib Treatment is Associated with Modest and Reversible Increases in Serum Lipids in Patients with Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2019 May 8. pii: S1542-3565(19)30491.
    PubMed     Abstract available


  139. GRILLER N, Cohen L
    Rapid Onset of Tofacitinib Induction Therapy for the Treatment of Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2019;17:1213.
    PubMed    


  140. FRAGAKI M, Demetriou G, Koutroubakis IE
    Risk Factors of Colectomy in Patients With Refractory Ulcerative Colitis Under Calcineurin Inhibitors Combined With Vedolizumab.
    Clin Gastroenterol Hepatol. 2019;17:1213-1214.
    PubMed    


  141. LAHARIE D, Pellet G
    Reply.
    Clin Gastroenterol Hepatol. 2019;17:1214-1215.
    PubMed    


    April 2019
  142. UNO Y
    Risk of Probiotics: Functional Gastrointestinal Symptoms in Patients with Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2019 Apr 17. pii: S1542-3565(19)30421.
    PubMed    


  143. WEINTRAUB Y, Cohen S, Chapnik N, Ben-Tov A, et al
    Clock Gene Disruption is an Initial Manifestation of Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2019 Apr 10. pii: S1542-3565(19)30373.
    PubMed     Abstract available


  144. ANANTHAKRISHNAN AN
    Reply to letter to the editor: Effect of Accelerated Infliximab Induction on Outcomes of Acute Severe Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2019 Apr 6. pii: S1542-3565(19)30365.
    PubMed    


    March 2019
  145. DAI C, Jiang M, Huang YH
    Effect of Accelerated Infliximab Induction on Outcomes of Acute Severe Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2019 Mar 27. pii: S1542-3565(19)30298.
    PubMed    


  146. EGBERG MD, Galanko JA, Kappelman MD
    Patients Who Undergo Colectomy for Pediatric Ulcerative Colitis at Low-volume Hospitals Have More Complications.
    Clin Gastroenterol Hepatol. 2019 Mar 7. pii: S1542-3565(19)30251.
    PubMed     Abstract available


  147. KHAN N, Lee H, Trivedi C, Kavani H, et al
    Mortality Associated With Development of Squamous Cell Cancer in Patients With Inflammatory Bowel Disease Receiving Treatment With Thiopurines.
    Clin Gastroenterol Hepatol. 2019 Mar 7. pii: S1542-3565(19)30254.
    PubMed     Abstract available


  148. ZANOLI L
    Increased Cardiovascular Risk in Patients With Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2019;17:799-800.
    PubMed    


  149. ANIWAN S, Loftus EV Jr
    Reply.
    Clin Gastroenterol Hepatol. 2019;17:800-801.
    PubMed    


  150. HIRTEN RP, Ghosh S, Colombel JF
    Reply.
    Clin Gastroenterol Hepatol. 2019;17:796-797.
    PubMed    


  151. LE BERRE C, Loeuille D, Peyrin-Biroulet L
    Combination Therapy With Vedolizumab and Tofacitinib in a Patient With Ulcerative Colitis and Spondyloarthropathy.
    Clin Gastroenterol Hepatol. 2019;17:794-796.
    PubMed    


    February 2019
  152. BURISCH J, Jess T
    Does eradication of Helicobacter pylori cause inflammatory bowel disease?
    Clin Gastroenterol Hepatol. 2019 Feb 12. pii: S1542-3565(19)30153.
    PubMed    


  153. GRACIE DJ, Ford AC
    Functional Gastrointestinal Symptoms in Inflammatory Bowel Disease: Rising to the Challenge.
    Clin Gastroenterol Hepatol. 2019;17:572-573.
    PubMed    


  154. MINER PB JR
    Effect of Treatment on the Risk of Viral Infections in Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2019 Feb 1. pii: S1542-3565(19)30137.
    PubMed    


  155. JOHNSON C, Binion DG
    Reply.
    Clin Gastroenterol Hepatol. 2019;17:576.
    PubMed    


  156. COLOMBEL JF, Shin A, Gibson PR
    Reply.
    Clin Gastroenterol Hepatol. 2019;17:573-574.
    PubMed    


  157. PARDI DS, Cotter TG, Loftus EV Jr
    Reply.
    Clin Gastroenterol Hepatol. 2019;17:572.
    PubMed    


  158. DULAI PS, Peyrin-Biroulet L
    Integrating Patient-Reported Outcomes Into Treat-to-Target Monitoring Algorithms.
    Clin Gastroenterol Hepatol. 2019;17:395-396.
    PubMed    


  159. VAN KRUININGEN HJ, Sura R
    Erroneous Use of Endoscopic Biopsy Data in Crohn's Disease.
    Clin Gastroenterol Hepatol. 2019;17:575-576.
    PubMed    


  160. MACALUSO FS, Cottone M, Orlando A
    Risk of Pneumonia Caused by Pneumocystis jiroveci in Inflammatory Bowel Disease: The Role of Concomitant Pulmonary Comorbidities.
    Clin Gastroenterol Hepatol. 2019;17:571-572.
    PubMed    


  161. COLOMBEL JF, Shin A, Gibson PR
    AGA Clinical Practice Update on Functional Gastrointestinal Symptoms in Patients With Inflammatory Bowel Disease: Expert Review.
    Clin Gastroenterol Hepatol. 2019;17:380-390.
    PubMed     Abstract available


  162. BEAUGERIE L, Kirchgesner J
    Balancing Benefit vs Risk of Immunosuppressive Therapy for Individual Patients With Inflammatory Bowel Diseases.
    Clin Gastroenterol Hepatol. 2019;17:370-379.
    PubMed     Abstract available


  163. NALAGATLA N, Falloon K, Tran G, Borren NZ, et al
    Effect of Accelerated Infliximab Induction on Short- and Long-term Outcomes of Acute Severe Ulcerative Colitis: A Retrospective Multicenter Study and Meta-analysis.
    Clin Gastroenterol Hepatol. 2019;17:502-509.
    PubMed     Abstract available


  164. NARULA N, Alshahrani AA, Yuan Y, Reinisch W, et al
    Patient-Reported Outcomes and Endoscopic Appearance of Ulcerative Colitis: A Systematic Review and Meta-analysis.
    Clin Gastroenterol Hepatol. 2019;17:411-418.
    PubMed     Abstract available


  165. SIMSEK M, Meijer B, Ramsoekh D, Bouma G, et al
    Clinical Course of Nodular Regenerative Hyperplasia in Thiopurine Treated Inflammatory Bowel Disease Patients.
    Clin Gastroenterol Hepatol. 2019;17:568-570.
    PubMed     Abstract available


  166. CHRISTENSEN B, Gibson PR, Micic D, Colman RJ, et al
    Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2019;17:486-493.
    PubMed     Abstract available


    January 2019
  167. FALECK DM, Winters A, Chablaney S, Shashi P, et al
    Shorter Disease Duration is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease but Not Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2019 Jan 5. pii: S1542-3565(19)30013.
    PubMed     Abstract available


  168. HANAUER S, Panaccione R, Danese S, Cheifetz A, et al
    Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2019;17:139-147.
    PubMed     Abstract available


  169. FEAGAN BG, Lasch K, Lissoos T, Cao C, et al
    Rapid Response to Vedolizumab Therapy in Biologic-Naive Patients With Inflammatory Bowel Diseases.
    Clin Gastroenterol Hepatol. 2019;17:130-138.
    PubMed     Abstract available


  170. KHALILI H, Hakansson N, Chan SS, Ludvigsson JF, et al
    No Association Between Consumption of Sweetened Beverages and Risk of Later-Onset Crohn's Disease or Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2019;17:123-129.
    PubMed     Abstract available


  171. KRUIS W, Neshta V, Pesegova M, Alekseeva O, et al
    Budesonide Suppositories Are Effective and Safe for Treating Acute Ulcerative Proctitis.
    Clin Gastroenterol Hepatol. 2019;17:98-106.
    PubMed     Abstract available


  172. ANANTHAKRISHNAN AN, Martin C, Kane S, Sandler RS, et al
    Paternal Disease Activity Is Associated With Difficulty in Conception Among Men With Inflammatory Bowel Diseases.
    Clin Gastroenterol Hepatol. 2019;17:203-204.
    PubMed     Abstract available


    December 2018
  173. RESTELLINI S, Chao CY, Martel M, Barkun A, et al
    Clinical Parameters Correlate With Endoscopic Activity of Ulcerative Colitis-a Systematic Review.
    Clin Gastroenterol Hepatol. 2018 Dec 21. pii: S1542-3565(18)31397.
    PubMed     Abstract available


  174. MA C, Kotze PG, Almutairdi A, Jairath V, et al
    Concomitant Use of Aminosalicylates Is Not Associated with Improved Outcomes in Patients with Ulcerative Colitis Escalated to Vedolizumab.
    Clin Gastroenterol Hepatol. 2018 Dec 7. pii: S1542-3565(18)31341.
    PubMed    


  175. WEAVER KN, Long MD
    Preventive Medicine in Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2018 Dec 6. pii: S1542-3565(18)31331.
    PubMed     Abstract available


    November 2018
  176. SANDBORN WJ, Panes J, D'Haens GR, Sands BE, et al
    Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials.
    Clin Gastroenterol Hepatol. 2018 Nov 23. pii: S1542-3565(18)31278.
    PubMed     Abstract available


  177. BERINSTEIN JA, Steiner CA, Regal RE, Allen JI, et al
    Efficacy of Induction Therapy with High-intensity Tofacitinib in 4 Patients with Acute Severe Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2018 Nov 17. pii: S1542-3565(18)31265.
    PubMed    


  178. TARGOWNIK LE, Benchimol EI, Bernstein CN, Singh H, et al
    Upfront Combination Therapy, Compared with Monotherapy, for Patients Not Previously Treated with a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study.
    Clin Gastroenterol Hepatol. 2018 Nov 15. pii: S1542-3565(18)31246.
    PubMed     Abstract available


    October 2018
  179. AXELRAD JE, Olen O, Askling J, Lebwohl B, et al
    Gastrointestinal Infection Increases Odds of Inflammatory Bowel Disease in a Nationwide Case-Control Study.
    Clin Gastroenterol Hepatol. 2018 Oct 30. pii: S1542-3565(18)31025.
    PubMed     Abstract available


  180. VANDE CASTEELE N, Jeyarajah J, Jairath V, Feagan BG, et al
    Infliximab Exposure-Response Relationship and Thresholds Associated with Endoscopic Healing in Patients With Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2018 Oct 26. pii: S1542-3565(18)31200.
    PubMed     Abstract available


  181. DAI C, Jiang M, Sun MJ
    The Association Between Consumption of Sweetened Beverages and the Risk of Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2018;16:1681-1682.
    PubMed    


  182. GOLDSMITH JR, Sartor RB
    Opioid Toxicity in Inflammatory Bowel Disease Patients Likely Includes Direct Enterocyte Effects That Exacerbate Disease.
    Clin Gastroenterol Hepatol. 2018;16:1679-1680.
    PubMed    


    September 2018
  183. HART AL, Bouri S
    Onset of action of Inflammatory Bowel Disease medications: how quickly do they really work?
    Clin Gastroenterol Hepatol. 2018 Sep 19. pii: S1542-3565(18)31012.
    PubMed    


  184. MORILLA I, Uzzan M, Laharie D, Cazals-Hatem D, et al
    Colonic microRNA Profiles, Identified by a Deep-learning Algorithm, That Predict Responses of Patients With Acute Severe Ulcerative Colitis to Therapy.
    Clin Gastroenterol Hepatol. 2018 Sep 14. pii: S1542-3565(18)30947.
    PubMed     Abstract available


  185. PELLET G, Stefanescu C, Carbonnel F, Peyrin-Biroulet L, et al
    Efficacy and Safety of Induction Therapy With Calcineurin Inhibitors in Combination with Vedolizumab in Patients With Refractory Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2018 Sep 10. pii: S1542-3565(18)30966.
    PubMed     Abstract available


  186. RAFFALS LE, Nguyen GC, Rubin DT, Nguyen GC, et al
    Switching Between Biologics and Biosimilars in Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2018 Sep 6. pii: S1542-3565(18)30943.
    PubMed    


  187. SOMINENI HK, Kugathasan S
    The microbiome in inflammatory bowel disease: from prevailing clinical evidence to future possibilities.
    Clin Gastroenterol Hepatol. 2018 Sep 6. pii: S1542-3565(18)30957.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: